[1] Berkhout R J, Tieben LM, Smits HL, et al.Nested PCR approach for detection and typing of epidermodysplasia verruciformisassociated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol, 1995, 33:690-695.
[2] Ramoz N, Rueda LA, Bouadjar B, et al. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J Invest Dermatol, 1999, 112:259-263.
[3] Ramoz N, Taieb A, Rueda LA, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J Invest Dermatol, 2000, 114:1148-1153.
[4] 魏羽佳,凌淑清,朱润衡,等.疣状表皮发育不良患者及家族的HLA系谱分析.中华皮肤科杂志,1994,27:167-168.
[5] Orth G. Epidermodysplasin verruciformis.In:Salzman NP, Howley PM, eds. The Papovaviridae; The Papillomaviruses. New Youk, NY:Plenum Publishing Corp, 1987.99-235.
[6] Favre M, Majewski S, De Jesus N, et al. A possible vertical transmission of human papillomavirus genotypes associated with epidermodysplasia verruciformis. J Invest Dermatol, 1998, 111:333-336.
[7] Cooper KD, Androphy EJ, Lowy D, et al.Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol, 1990, 94:769-776.
[8] Majewski S, Malejczyk J, Jablonska S, et al.Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis. J Am Acad Dermatol, 1990, 22:423-427.
[9] Jablonska S. Epidermodysplasin verruciformis. In:Friedman RJ, ed. Cancer of the skin. Philadelphia, Pa; WB Saunders Co,1991. 101-113.
[10] Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis:human papillomavirus -associated cutaneous changes need over 20 years for malignant conversion. Cancer Res, 1997, 57:4214-4216.
[11] Jacyk WK, De Villiers EM. Epidermodysplasia verruciformis in Africans. Int J Dermatol, 1993, 32:806-810.
[12] Padlewska K, Ramoz N, Cassonnet P, et al.Mutation and abnormal expression of the p53 gene in the viral skin carcinogenesis of epidermodysplasia verruciformis. J Invest Dermatol, 2001, 117:935-942.
[13] Preiser W, Kapur N, Snoeck R, et al. No apparent effect of cidofovir in epidermodysplasia verruciformis. J Clin Virol, 2000, 16:55-57.
[14] Iraji F, Faghihi G. Epidermodysplasia verruciformis:association with isolated IgM deficiency and response to treatment with acitretin. Clin Exp Dermatol, 2000, 25:41-43.
[15] 刘之力,史月君,刘新国.异维A酸联合他扎罗汀凝胶治疗疣状表皮发育不良一例.中华皮肤科杂志,2003,36:233.
[16] Anadolu R, Oskay T, Erdem C, et al. Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol, 2001, 45:296-299.
[17] Hayashi J, Matsui C, Mitsuishi T, et al.Treatment of localized epidermodysplasia verruciformis with tacalcitol ointment. Int J Dermatol, 2002, 41:817-820.
[18] Micali G, Nasca MR, Dall'Oglio F, et al.Cimetidine therapy for epidermodysplasia verruciformis. J Am Acad Dermatol, 2003,48:S9-S10.
[19] 胡兹嘉,张宝民,方方.异维A酸联合手术治疗疣状表皮发育不良一例.中华皮肤科杂志,1998,31:196.
[20] Karrer S, Szeimies RM, Abels C, et al. Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol, 1999, 140:935-938. |
